Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.73 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.73 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600192 | 0.92 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL1012616 | 0.92 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1783390 | 0.91 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL4510854 | 0.91 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL378957 | 0.91 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL12650389 | 0.90 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL1013690 | 0.90 | MAPK13 (0.59) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1409741 | 0.89 | MAPK13 (0.59) | MAPK14MAPK13MAPK12MAPK11NTRK1 | |
| SCHEMBL1793950 | 0.89 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1012997 | 0.89 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180086741-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9850233-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9701670-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160318909-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150218137-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20180086741-A1 | KINASE INHIBITORS | SYK, BTK, SRC | MAPK14 89/4885MAPK13 77/4885MAPK12 124/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 80/4885MAPK13 76/4885MAPK12 124/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20150218137-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | SYK, BTK, LYN | MAPK14 105/4885MAPK13 132/4885MAPK12 194/4885 |
| US-20160318909-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 143/4885MAPK13 67/4885MAPK12 179/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
| US-20140057915-A1 | KINASE INHIBITORS | SYK, BTK, LYN | MAPK14 88/4885MAPK13 112/4885MAPK12 129/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK14 145/4885MAPK13 117/4885MAPK12 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.